Compare Enovix Corporation (ENVX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Zoetis Inc — how do they compare? Enovix Corporation trades at $2.47 (market cap $549.72M), while Zoetis Inc trades at $74.35 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 54.9× Enovix Corporation's market cap, and Zoetis Inc pays a 2.9% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Zoetis Inc for 70 Days on average.
| ENVX | ZTS | |
|---|---|---|
Market Cap | $549.72M | $30.20B |
Volume | 6,635,687 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $13.19 | $147.53 |
52-Week Low | $2.50 | $69.09 |
Typical Hold Time | 11 Days | 70 Days |
Enterprise Value | $611.42M | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.46, down 3.53% on the day, reflecting a bearish technical trend. The company is in a high-growth investment phase, with revenue growing to $36 million in 2026 but reporting significant losses. Recent news highlights a CEO transition and progress in battery manufacturing for defense and consumer electronics, while analyst consensus remains largely positive with a $10.75 price target.
The outlook is bifurcated: strong analyst buy ratings and institutional interest signal long-term potential, but high cash burn, persistent losses, and bearish technical indicators present substantial near-term risks. Investment hinges on successful commercialization and achieving profitability from current expansion efforts.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
